Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

Eculizumab is first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH); however, approximately 11-27% of patients may experience breakthrough hemolysis (BTH) on approved doses of eculizumab. Ravulizumab, a new long-acting C5 inhibitor with a four times longer mean half-life than eculizumab...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Haematologica
Hoofdauteurs: Brodsky, Robert A., de Latour, Régis Peffault, Rottinghaus, Scott T., Röth, Alexander, Risitano, Antonio M., Weitz, Ilene C., Hillmen, Peter, Maciejewski, Jaroslaw P., Szer, Jeff, Lee, Jong Wook, Kulasekararaj, Austin G., Volles, Lori, Damokosh, Andrew I., Ortiz, Stephan, Shafner, Lori, Liu, Peng, Hill, Anita, Schrezenmeier, Hubert
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Fondazione Ferrata Storti 2020
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7776354/
https://ncbi.nlm.nih.gov/pubmed/31949012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.236877
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items